India, May 15 -- OS Therapies, Inc. (OSTX), a clinical-stage biopharma company specializing in immunotherapies and antibody-drug conjugates, has launched a new subsidiary, OS Animal Health, Inc., to lead the commercialization of its immunotherapy candidate OST-HER2 for canine osteosarcoma.
The market opportunity for OST-HER2 in treating canine osteosarcoma is estimated to exceed $150 million in the U.S. annually. This projection is supported by recent clinical data demonstrating the drug's effectiveness in both preventing amputations in frontline treatment and controlling metastases. These findings build on earlier data that previously secured a conditional USDA approval for OST-HER2 based on improved overall survival rates post-amputation...